文献速递中医内科中药与中成药合理使用

抑制TGF-β激活的肌成纤维细胞分化区分两种含丹参中药复方抗肺纤维化疗效

Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions.
PubMed 文献 · Front Pharmacol · 2019-04-24

本研究在博来霉素诱导的小鼠肺纤维化模型中,比较含丹参的丹蒌方与丹红方的疗效。μCT可无创监测和量化肺纤维化及疗效;丹蒌方抑制TGF-β信号激活的肌成纤维细胞分化和α-SMA表达,减轻肺纤维化,而丹红方无此效果。网络药理学提示丹蒌方成分调控炎症及肌成纤维细胞活化、胶原沉积相关基因。

要点

  • 丹蒌方可减轻博来霉素诱导的小鼠肺纤维化,丹红方未见此效果。
  • 丹蒌方抑制TGF-β信号激活的肌成纤维细胞分化和α-SMA表达。
  • μCT可无创监测和量化啮齿类肺纤维化及中药疗效。

核心结论

  • 含丹参的丹蒌方而非丹红方可减轻博来霉素诱导的小鼠肺纤维化,机制与抑制TGF-β信号激活的肌成纤维细胞分化相关。

研究设计与样本

  • 在博来霉素诱导的小鼠肺纤维化模型中比较丹蒌方与丹红方的疗效,并采用μCT、组织病理学和免疫组化评估。
  • 采用Ingenuity Pathways Analysis系统对丹蒌方或丹红方进行药物-靶点相互作用的网络药理学分析。

主要发现

  • μCT可有效监测和量化博来霉素诱导的啮齿类肺纤维化及中药复方治疗疗效。
  • 丹蒌方减轻博来霉素诱导的肺纤维化,丹红方未减轻。
  • 丹蒌方抑制TGF-β信号激活的肌成纤维细胞分化和α-SMA表达。
  • IPA核心分析显示丹蒌方成分调控肺纤维化相关炎症基因及肌成纤维细胞活化和胶原沉积相关基因。

临床怎么用

  • 基于中医「痰瘀互结」理论,临床有效的心血管中药复方丹蒌方可能被重新用于治疗肺纤维化。
  • 治疗肺纤维化可能需要同时抑制促炎和促纤维化通路,兼顾「化痰」与「活血」的复方可能更好实现心肺共保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment options. It also leads to progressive respiratory failure, which subsequently affects the heart functionality, a pathological heart-lung interaction increasingly noticed and defined as pulmonary-heart disease (PHD). Traditional Chinese medicine (TCM) theory for treating "phlegm-stasis cementation syndrome" may suggest a possibility of treating PHD complication with Chinese medicine prescriptions previously used for cardiovascular diseases. Methods: Here, we evaluate the efficacies of two compound Chinese medicine prescriptions, Danlou prescription (DLP) and Danhong prescription (DHP), which share a common herbal component, Salvia miltiorrhiza (Danshen), on pulmonary fibrosis. Severity grades of Bleomycin (BLM)-induced pulmonary fibrosis were assessed by micro-Computerized Tomography (μCT) in accordance with the clinical evaluation standard. Lung pathological changes and collagen deposition were investigated by histopathology. Myofibroblast differentiation was assessed by immunohistochemistry of α-SMA and TGF-β receptor type II expression in situ. Network pharmacology analysis of the drug-target interaction in IPF progression for DLP or DHP was performed using Ingenuity® Pathways Analysis (IPA) system. Results: We show that a non-invasive μCT effectively monitor and quantify BLM-induced pulmonary fibrosis and its treatment efficacy by Chinese medicine prescription in rodents. In addition, although both containing Salvia miltiorrhiza, DLP but not DHP mitigates BLM-induced lung fibrosis by inhibiting the TGF-β signaling-activated myofibroblast differentiation and α-SMA expression in a mouse model. Core analysis by IPA revealed that DLP ingredients regulated not only pulmonary fibrosis related inflammatory genes but also genes associated with myofibroblast activation and collagen deposition. Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of "removing both phlegm and blood stasis" will better achieve co-protection of heart and lung in PHD.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shao R, Wang FJ, Lyu M, et al. Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions. Front Pharmacol. 2019. PMID: 31105564. doi:10.3389/fphar.2019.00412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。